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esponsibility of InstAbstract Coxsackievirus B type 3 (CVB3) is one of the major causative pathogens associated with viral
meningitis and myocarditis, which are widespread in the human population and especially prevalent in neonates
and children. These infections can result in dilated cardiomyopathy (DCM) and other severe clinical
complications. There are no vaccines or drugs approved for the prevention or therapy of CVB3-induced
diseases. During screening for anti-CVB3 candidates in our previous studies, we found that jiadifenoic acids C
exhibited strong antiviral activities against CVB3 as well as other strains of Coxsackie B viruses (CVBs). The
present studies were carried out to evaluate the antiviral activities of jiadifenoic acids C. Results showed that
jiadifenoic acids C could reduce CVB3 RNA and proteins synthesis in a dose-dependent manner. Jiadifenoic
acids C also had a similar antiviral effect on the pleconaril-resistant variant of CVB3. We further examined the
impact of jiadifenoic acids C on the synthesis of viral structural and non-structural proteins, ﬁnding that
jiadifenoic acids C could reduce VP1 and 3D protein production. A time-course study with Vero cells showed
that jiadifenoic acids C displayed signiﬁcant antiviral activities at 0–6 h after CVB3 inoculation, indicating that
jiadifenoic acids C functioned at an early step of CVB3 replication. However, jiadifenoic acids C had no
prophylactic effect against CVB3. Taken together, we show that jiadifenoic acids C exhibit strong antiviral8
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Miao Ge et al.278activities against all strains of CVB, including the pleconaril-resistant variant. Our study could provide a
signiﬁcant lead for anti-CVB3 drug development.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Figure 1 The chemical structure of jiadifenoic acids C.1. Introduction
Coxsackie B viruses, belonging to the Enterovirus genus of the
Picornaviridae family, can cause a broad spectrum of human
diseases, and are especially prevalent in neonates and children1.
Although the diseases they induce are often mild, such as the
common cold, or remain asymptomatic at early stages1,2, they can
develop into severe and fatal diseases like aseptic meningitis, acute
and chronic myocarditis, paralytic diseases, rhabdomyolysis, pleur-
odynia (Bornholm's disease), pancreatitis, hepatitis, insulin-
dependent diabetes mellitus, and severe septic disease1,3. Among
these, CVB3 is a frequent subtype. It is also one of the major
causative agents of chronic, sub-acute, acute, and fulminant
myocarditis as well as pancreatitis and aseptic meningitis. It has
been reported that more than 50% of human myocarditis is
attributable to CVB3 infection. It is estimated that about
10%–20% of people (approximately 20,000–40,000 patients/year
in the USA) with symptoms of acute myocarditis induced by CVB3
infection will develop chronic disease, and chronic myocarditis
progresses to DCM at a frequency of 3.5–8.5 cases per 100,000
persons (9000–20,000 new cases/year in the USA)1, often requiring
heart transplantation4. It can even infect stem cells in the neonatal
central nervous system4, and CVB3 may also trigger the onset of type
1 diabetes mellitus5. So it often does great harm to patients' hearts,
pancreases and central nervous systems, especially in neonates, young
children and immunocompromised adult patients6.
CVB3 is a small, non-enveloped, single-stranded and positive-
sense RNA virus2,6,7. The whole genome of CVB3 is 7.4 kb in
length that can encode a large polyprotein. There is a non-
translated region (NTR) at both the 50and 30 termini of the RNA
genome. The 50-NTR consists of 742 nt and also has the
indispensable factors that are required for synthesis and translation
of the genome, such as an internal ribosomal entry site (IRES)1,
which leads to ribosomal entry and initiates translation of the
uncapped RNA genome. The large polyprotein is translated from
an open reading frame into a single polypeptide. After translation,
the mature viral proteins are released by viral proteinases 2A and
3C as three precursor proteins (P1, P2 and P3) and then processed
into the individual proteins. The P1 precursor protein is further
processed into the four capsid proteins, VP0 (which is further
cleaved to VP4 and VP2), VP3 and VP1. The P2 and P3 precursor
proteins are processed into seven non-structural proteins1,6.
Ultimately the CVB virus is composed of four capsid proteins
(VP1, VP2, VP3, and VP4)8 and seven non-structural proteins
(2A, 2B, 2C, 3A, 3B, 3C, 3D), in which the VP1 protein locates
on the surface of the viral capsid, playing an important role in
targeting host cells. Inside there is a hydrophobic pocket which is
the binding site of the various pocket factors and small antiviral
compounds9,10.
As to the infection of a permissive host cell, CVB3 mainly binds to
two speciﬁc cell surface receptors, the coxsackievirus and adenovirus
receptor (CAR) or the membrane protein decay accelerating factor
(DAF). It is generally accepted that CAR acts as the main entry routefor CVB3 internalization since some CVB3 strains do not use DAF as
a co-receptor4,11. Receptors interacting with the virus induce the release
of the pocket factor and conformational changes in the capsid, which
allows the viral RNA to enter host cells. This step can be blocked by
capsid inhibitors, such as the ‘WIN’ compounds12,13. They may replace
the pocket factor and occupy the hydrophobic pocket to prevent virus
attachment to cell receptors and prevent conformational changes in
the viral capsid, thus preventing the release of the viral RNA from the
capsid14,15. However, replacement of Ile-1092 with Leu or Met in
the hydrophobic pocket of VP1 results in drug resistance16,17. So far, in
spite of extensive efforts, there is no approved vaccine or antiviral drug
for prevention or therapy of CVB3-induced diseases1. Moreover, no
single enterovirus serotype is exclusively associated with a particular
disease, and enterovirus serotypes are numerous17. Thus, searching for
drugs with a broad antiviral spectrum especially effective on the
pleconaril-resistant CVB3 strain is important and necessary.
In a large-scale screening for novel drug candidates against
CVB3, we found jiadifenoic acids C (Fig. 1) were able to prevent
CVB3 replication. Jiadifenoic acid C, an abietane-type diterpene,
was ﬁrst isolated from the roots of Illicium jiadifengpi which is used
as a traditional Chinese medicine for the treatment of rheumatism18.
In the present study, we have demonstrated the antiviral effect
of jiadifenoic acids C against the wild-type strain and the
pleconaril-resistant variant of CVB3 as well as other strains of
CVBs. We also evaluated its effect on reducing CVB3 RNA and
protein synthesis as well as its action phase of inhibiting CVB3
replication. Finally, we examined the effect of jiadifenoic acids C
on the structural and non-structural viral proteins.2. Materials and methods
2.1. Cells and virus
African green monkey kidney cells (Vero) were purchased from the
American Type Culture Collection and cultured in MEM supplemented
with 10% FBS and antibiotics (100 U/mL penicillin G, 100 μg/mL
streptomycin) at 37 1C in the presence of 5% CO2.
CVB3 (strain Nancy) was obtained from the American Type
Culture Collection and propagated in Vero cells. CVB1 (strain
Conn-5), CVB2 (strain Ohio-1), CVB4 (strain J.V.B.), CVB5 (strain
Faulkner) and CVB6 (strain Schmitt) were all obtained from the
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The pleconaril-resistant variant of CVB3 (strain Nancy) was
produced by our lab. Brieﬂy, Vero cells (3 105 cells/well) were
plated into 24-well culture plates and incubated for 16 h. Cells
infected with 200 mL CVB3 (Nancy) at 1000 TCID50 and 100
TCID50, respectively, for 1 h were supplemented with suitable
concentrations of jiadifenoic acids C during incubation. When the
CPE of cells treated with jiadifenoic acids C reached 4, the virus
was collected by centrifugation at 5000 rpm for 15 min at 4 1C
after freezing and thawing in 80 1C for three times. The
pleconaril-resistant variant of CVB3 was isolated after repeating
these steps thirteen-fold19.
The plasmids, including pEGFP-VP1, pEGFP-VP4-VP2-VP3
(pEGFP-VP4-3), pEGFP-2C, pEGFP-3A, pEGFP-3B, pEGFP-3C
and pEGFP-3D, were all kindly provided by Professor Zhaohua
Zhong, Department of Microbiology, Harbin Medical University.
2.2. Compounds
Jiadifenoic acids C were kindly provided by Professor Shishan Yu,
State Key Laboratory of Bioactive Substance and Function of
Natural Medicines, Institute of Materia Medica, Chinese Academy
of Medical Sciences and Peking Union Medical College. Pleconaril
was kindly provided by Professor Xianjin Luo, School of Chemistry
and Chemical Engineering, Shanghai Jiaotong University. Ribavirin
(RBV) injection (100 mg/mL) was provided by Hangzhou Min-
sheng Pharmaceutical Co., Ltd.
2.3. Cytotoxicity assay
The cytotoxic effect of jiadifenoic acids C on Vero cells was
assayed by CPE. Brieﬂy, cells (3 104 cells/well) were seeded
into 96-well culture plates and incubated overnight at 37 1C under
5% CO2. The medium was removed and different concentrations
(0.82, 2.47, 7.41, 22.22, 66.67 and 200 mg/mL) of jiadifenoic acids
C were applied. The result was measured with three repeats and
the experiment performed in triplicate. After 3 days' incubation,
the cytotoxicity of jiadifenoic acids C was determined by CPE
assay. TC50 was deﬁned as the concentration that inhibits 50%
cellular growth in comparison with untreated controls, and
calculated by the Reed and Muench method.
2.4. CPE inhibition assay for anti-CVB3
The anti-CVB3 activity of jiadifenoic acids C was also assayed by
the CPE method. Brieﬂy, cells (3 104 cells/well) were plated into
96-well culture plates and incubated for 16 h. The medium was
removed and cells were infected with 100 mL CVB3 of 100
TCID50 for 1 h, after which various concentrations of jiadifenoic
acids C were added immediately for incubation until the CPE of
the control group cells reached 4. Each experiment was tested in
triplicate and performed at least thrice separately. The 50%
inhibitory concentration (IC50) was determined by the Reed and
Muench method. The selectivity index (SI) was calculated as the
ratio of TC50/IC50.
2.5. RT-PCR quantiﬁcation of CVB3 RNA
Vero cells (9 105 cells/well) were plated into 6-well culture plates
and incubated for 16 h. The medium was removed and cells were
infected with 600 mL CVB3 (Nancy) of 100 TCID50 for 1 h, afterwhich various concentrations of jiadifenoic acids C were added
immediately for incubation for another 24 h. Cellular and total viral
RNA were extracted from infected cells using the RNeasy Mini kit
(QIAGEN) according to the manufacturer's instructions.
One-step quantitative real-time polymerase chain reaction
(qRT-PCR) was carried out using the ABI 7500 Fast Real-Time
PCR system (Applied Biosystems) with SuperScript III Platinum
SYBR Green One-step RT PCR Kit (invitrogen) and CVB3
forward primer (50-TGCTCCGCAGTTAGGATTAGC-30) and
reverse primer (50-ACATGGTGCGAAGAGTCTATTGAG-30)
targeting a conserved region of the VP1 gene20, using β-actin as
internal control with the forward primer (50-TGACGGGGTCACC-
CACACTGTGCCCATCTA-30) and reverse primer (50-CTA-
GAAGCATTTGCGGTGGACGATG-30)21.
The PCR assay was carried out in a volume of 25 μL consisting
of 12.5 μL of 2 SYBR Green Reaction Mix, 0.5 μL of 10 μmol/L
of each oligonucleotide primer, 0.5 μL of SuperScript III RT/
Platinum Tap Mix, 1 μL ROX Reference and 1 μL of RNA extracted
from the samples. The target fragment ampliﬁcation was carried out
as follows: reverse transcription at 50 1C for 3 min; initial activation
of HotStar Taq DNA Polymerase at 95 1C for 5 min; 40 cycles in
two steps: 95 1C for 15 s, 60 1C for 30 s. At the end of the
ampliﬁcation cycles melting temperature analysis was carried out
by a slow increase in temperature (0.1 1C/s) up to 95 1C.2.6. Western blot analysis of CVB3 protein
Vero cells (9 105 cells/well) were plated into 6-well culture plates
for incubation for 16 h. The medium was removed and the cells were
infected with 600 mL CVB3 (Nancy) of 100 TCID50 for 1 h, after
which various concentrations of jiadifenoic acids C were added
immediately for incubation for 36 h. After incubation, the cells were
rapidly washed with ice-cold PBS and ice-cold M-PER mammalian
protein extraction reagent (Thermo) containing halt protease inhibitor
single-use cocktail (Thermo) was added. The cells were scraped,
collected and lysed for 30 min. The cell lysates were centrifuged at
12,000 g for 15 min at 4 1C to yield the whole cell extract. The
protein concentration was determined by the BCA assay (Thermo)
according to the instructions of the manufacturer. Samples from these
supernatant fractions (10 μg protein) were denatured and subjected to
SDS–PAGE using a 10% (w/v) running gel. Proteins were transferred
to a PVDF membrane and the membrane was incubated successively
at room temperature with 5% (w/v) non-fat milk in TBST for 1 h.
Membranes were then incubated at room temperature using an mouse
anti-coxsackie virus B3 monoclonal antibody (Millipore) and an anti-
β-actin (Cell Signaling) antibody used at a dilution of 1:1000 and
1:3000 in 3% (w/v) non-fat milk for 2 h21. The membranes were
washed with TBST 3 times for 10 min each and incubated with a
1:5000 dilution of anti-mouse horseradish peroxidase antibody (Cell
Signaling) for 1 h. Following each incubation, the membrane was
washed extensively with TBST.2.7. Time course assay
The antiviral activity of jiadifenoic acids C was also examined at
different time periods before and after viral infection. Brieﬂy, cells
(3 104 cells/well) were seeded and incubated for 16 h as
previously described. The cell monolayer was then infected with
100 mL CVB3 (Nancy) at a multiplicity of infection (MOI) of 1 for
1 h. 80 μg/mL jiadifenoic acids C in 100 μL were added following
Miao Ge et al.280the protocol. The cells were incubated until the CPE of the control
group cells reached 4 and then assayed with the CPE assay.
2.8. Western blot analysis of CVB3's structural and
non-structural proteins
Vero cells (9 105 cells/well) were plated into 6-well culture plates
for incubation for 16 h. The medium was removed and cells were
transfected with 4 μg of plasmids expressing the EGFP-tagged VP1,
VP4-3, 2A, 2B, 2C, 3A, 3B, 3C, and 3D, respectively (pEGFP-VP1,
pEGFP-VP4-VP2-VP3 (pEGFP-VP4-3), pEGFP-2C, pEGFP-3A,
pEGFP-3B, pEGFP-3C and pEGFP-3D), using Lipofectamine 2000
Reagent (invitrogen) and opti-MEM (1 ) Reduced Serum Medium
(Gibco) according to the instructions of the manufacturer. After 48 h,
the medium was removed and the cells were treated with various
concentrations (0, 10, 20, 40 and 80 μg/mL) of jiadifenoic acids C for
incubation for another 36 h. The cells were harvested for western blot
assay as described above.
2.9. CPE inhibition assay for anti-coxsackievirus B type
The anti-coxsackievirus activity of jiadifenoic acids C also was
assayed by the CPE method. Brieﬂy, cells (3 104 cells/well) were
plated into 96-well culture plates and incubated for 16 h. The medium
was removed and the cells were infected with 100 mL coxsackievirus
at 100 TCID50 for 1 h, after which various concentrations of
jiadifenoic acids C were added immediately for incubation until the
CPE of the control group cells reached 4. Each experiment was
measured in triplicate and performed at least thrice separately. The
IC50 was determined by the Reed and Muench method. The SI was
calculated as the ratio of TC50/IC50.Figure 2 Inhibition of CVB3-induced CPE by jiadifenoic acids C. Conﬂ
After 1 h of adsorption at 37 1C, the monolayers were washed with PBS an
with or without various concentrations of jiadifenoic acids C. The morpholo
group cells reached 4.3. Results
3.1. Inhibition of CVB3 replication by jiadifenoic
acids C in vitro
The cytotoxic effect of jiadifenoic acids C on Vero cells was
measured with a conventional CPE method, and the TC50 was
115.47 mg/mL. We used a CPE reduction assay to study the anti-
CVB3 activities of jiadifenoic acids C. As shown in Fig. 2,
jiadifenoic acids C signiﬁcantly reduced CVB3-induced CPE in a
dose-dependent manner. The IC50 and selectivity index of
jiadifenoic acids C for CVB3 infection in Vero cells are shown
in Table 1.3.2. Inhibition of viral RNA synthesis by jiadifenoic acids C
To examine the effect of jiadifenoic acids C on the synthesis of
CVB3 RNA, the CVB3 (Nancy)-infected cells were treated with
jiadifenoic acids C and the viral RNA in cells was extracted and
analyzed using the RT-PCR assay. As shown in Fig. 3, jiadifenoic
acids C inhibited viral RNA synthesis in a dose-dependent manner.3.3. Inhibition of viral protein synthesis by jiadifenoic acids C
To examine the effect of jiadifenoic acids C on the synthesis of
CVB3 proteins, the CVB3 (Nancy)-infected cells were treated with
jiadifenoic acids C and the viral proteins in the cells were analyzed
using western blotting. As shown in Fig. 4, jiadifenoic acids C
inhibited the viral protein synthesis in a dose-dependent manner.uent Vero cultures were inoculated with 100 TCID50 CVB3 (Nancy).
d incubated at 37 1C in the maintenance medium (MEM plus 2% FBS)
gical changes in Vero cells were observed until the CPE of the control
Table 1 Antiviral activities of jiadifenoic acids C against CVB3 in vitro.
CVB3 (Nancy) Jiadifenoic acids C Pleconaril RBV
TC50 (μg/mL) IC50 (μg/mL) SI TC50 (μg/mL) IC50 (ng/mL) SI TC50 (mg/mL) IC50 (μg/mL) SI
Standard strain 115.47 18.63710 6.19 15.41 0.3870.1 40553 410 366774 427.3
Resistant strain 115.47 52.58719.9 2.2 15.41 13.873.55 1117 410 515775 419.4
Figure 3 Jiadifenoic acids C reduce CVB3 viral RNA synthesis in
Vero cells. Vero cells (9 105 cells/well) were plated into 6-well
culture plates for incubation for 16 h. The medium was removed and
cells were infected with 600 μL CVB3 of 100 TCID50 for 1 h, after
which various concentrations of jiadifenoic acids C were added
immediately and the incubation continued for 24 h. The cells were
harvested for one-step qRT-PCR assay. *Po0.001 vs control.
Figure 4 Jiadifenoic acids C reduces CVB3 viral proteins (VP1)
synthesis in Vero cells by western blot assay. Vero cells (9 105 cells/
well) were plated into 6-well culture plates for incubation for 16 h. The
medium was removed and cells were infected with 600 μL CVB3
(Nancy) of 100 TCID50 for 1 h, after which various concentrations of
jiadifenoic acids C were added and incubation continued for 36 h. The
cells were harvested for western blot assay.
Figure 5 Time course assay of jiadifenoic acids C against CVB3.
(a) An illustration of the treatment with jiadifenoic acids C. Conﬂuent
Vero cells were inoculated with CVB3 (Nancy) at a multiplicity of
infection (MOI) of 1 for 1 h. Jiadifenoic acids C (80 mg/mL) were
added at the designated times. (b) The morphological changes in Vero
cells were observed until the CPE of the control group cells reached 4.
The results show CPE induced by CVB3 infection with or without
jiadifenoic acids C treatment, and the virus control group is set
as 100%.
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To examine the action phase of jiadifenoic acids C in inhibiting
CVB3, the CVB3 (Nancy)-infected cells were treated with
80 mg/mL jiadifenoic acids C and the viral suppression rate in
cells was analyzed using CPE. As shown in Fig. 5, treatment with
jiadifenoic acids C at 0–6 h after CVB3 infection inhibited viral
replication, while they were ineffective at 8 h and 8 to 1 h of
CVB3 infection.
3.5. Inhibition of the synthesis of various viral structural
proteins and non-structural proteins by jiadifenoic acids C
To examine which viral components are affected by jiadifenoic
acids C, Vero cells were transfected with plasmids expressing the
EGFP-tagged VP1, VP4-3, 2A, 2B, 2C, 3A, 3B, 3C and 3D,
respectively. After 48 h the medium was removed and cells were
treated with various concentrations of jiadifenoic acids C for
incubation for another 36 h, and the cells were harvested for
western blot assay. As shown in Fig. 6, jiadifenoic acids C could
reduce the EGFP-VP1 and EGFP-3D production in a dose-
dependent manner.
3.6. Inhibition of coxsackievirus B-type replication
by jiadifenoic acids C in vitro
The CPE reduction assay was used to study anti-coxsackievirus B-
type activities of jiadifenoic acids C. Indeed, jiadifenoic acids Cexhibited activities against CVB1, B2, B3, B4, B5 and B6 in Vero
cells. The IC50 and selectivity index of jiadifenoic acids C for
CVBs infections are shown in Table 2.
Figure 6 Jiadifenoic acids C reduce CVB3 viral proteins (VP1 and 3D) synthesis in Vero cells by western blot assay. Vero cells (9 105 cells/
well) were plated into 6-well culture plates for incubation for 16 h. The medium was removed and cells were transfected with 4 μg plasmids
pEGFP-VP1, pEGFP-VP4-VP2-VP3 (pEGFP-VP4-3), pEGFP-2C, pEGFP-3A, pEGFP-3B, pEGFP-3C and pEGFP-3D. After 48 h cells were
treated with various concentrations of jiadifenoic acids C and incubation continued for 36 h. The cells were harvested for western blot assay.
Table 2 Antiviral activities of jiadifenoic acids C against coxsackievirus in vitro.
Virus Jiadifenoic acids C Pleconaril RBV
TC50 (μg/mL) IC50 (μg/mL) SI TC50 (μg/mL) IC50 (ng/mL) SI TC50 (mg/mL) IC50 (μg/mL) SI
CVB1 115.47 5.0571.46 22.87 15.41 0.88570.095 17,412 410 515775 419.42
CVB2 115.47 10.974.3 10.59 15.41 0.570.16 (μg/mL) 30.82 410 554737 418.05
CVB4 115.47 25.16715.8 4.59 15.41 2.8171.5 5484 410 3317109 430.21
CVB5 115.47 6.0371.9 19.15 15.41 1.1370.75 13,637 410 605715 416.53
CVB6 115.47 13.971.5 8.31 15.41 6.4671 2385 410 366774 429.76
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Myocarditis is inﬂammation of the myocardium which most
frequently follows enterovirus (picornavirus family) infection8.
CVBs represent the most commonly identiﬁed infectious agents
associated with acute and chronic myocarditis. CVB3 is one of the
most common viral etiologic variants3. It can induce severe
infections towards heart, pancreas and brain. In recent years theincidence rate appears to be rising in China. However, its speciﬁc
pathogenesis has not been fully understood yet. And to date there
is no approved vaccine or antiviral drug for prevention or therapy
of CVB3-induced diseases1. Moreover, there are large numbers of
enterovirus serotypes and no single enterovirus serotype is
exclusively associated with a particular disease. Thus, the search
for drugs with a broad antiviral spectrum to prevent and treat
myocarditis is timely.
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secondary metabolites isolated from plants and have a wide
spectrum of useful biological activities. Jiadifenoic acid C, an
abietane-type diterpene, was ﬁrst isolated from the roots of Illicium
jiadifengpi which is used as a traditional Chinese medicine for the
treatment of rheumatism18. In our previous study, jiadifenoic acid
C was reported to exhibit antiviral activities against CVB2, B3,
B4, and B6. In order to evaluate jiadifenoic acids C in a more
systematic manner, we carried out a series of experiments.
In this study, the antiviral effects of jiadifenoic acids C against
all strains of CVBs have been demonstrated. Jiadifenoic acids C
could reduce CVB3 RNA and protein synthesis in a dose-
dependent manner. It could also prevent the replication of a
pleconaril-resistant CVB3 variant. A time-course study showed
that jiadifenoic acids C functions at an early step of CVB3
replication but has no prophylactic effect against CVB3, suggest-
ing that it most likely does not inhibit CVB3 entry and uncoating,
but suppresses viral RNA/protein biosynthesis. Moreover, the
initial analysis of the effect of jiadifenoic acids C on VP1, VP2-
4, 2C, 3A, 3B, 3C, and 3D showed that jiadifenoic acids C could
inhibit viral protein VP1 and 3D expression in plasmid-transfected
cells, indicating that jiadifenoic acids C's antiviral effects may be
associated with structural protein VP1 and non-structural protein
3D. However, as the viral proteins' expression in the plasmid-
transfected cells did not rely on viral replication, but depended on
host cellular transcription and translation machinery, it was unclear
how the selective reduction of the two viral proteins was
accomplished. Perhaps it is because jiadifenoic acids C could
promote the degradation of these viral proteins. Since jiadifenoic
acids C have a similar effect on both the pleconaril-resistant
variant of CVB3 and the wild-type strain, we suppose that it most
likely inhibits CVB3 replication in a different way than does
pleconaril. The 3D protein is the viral RNA-dependent RNA
polymerase (RdRp), which plays an essential role in the replication
machinery of RNA viruses22,23. How jiadifenoic acids C promote
viral 3D protein degradation in a dose-dependent manner remains
unresolved, and requires further exploration.
Although CVB3 is known to be a potent pathogen that can
cause acute or chronic cardiac-related diseases as deﬁned by the
Dallas criteria, CVB3-speciﬁc prophylactic or therapeutic proce-
dures are lacking. Jiadifenoic acids C can actively inhibit replica-
tion of CVBs as well as the pleconaril-resistant CVB3. Our
ﬁndings may provide a signiﬁcant lead for anti-CVB3 drug
optimization and development as well as DCM therapy. We will
continue to clarify the mechanism by which jiadifenoic acids C
mediate their antiviral effects.Acknowledgments
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